The present invention relates to a cosmetic or pharmaceutical, preferably dermatological, composition comprising or consisting of a liquid lipophilic component and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or for animal care. Additionally, the present invention relates to the use of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or of a mixture of two or more different specific alkanediols for improving the sensory properties, i.e. skin sensation, of a cosmetic or pharmaceutical composition upon topical application, or as silicone replacer.

The present invention relates to a cosmetic or pharmaceutical, preferably dermatological, composition or a homecare product comprising or consisting of a natural polymer and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and said compositions for personal care, as a pharmaceutical, for animal care or for homecare. Additionally, the present invention relates to the use of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols in an effective amount for reducing antimicrobial load of a natural polymer and/or as an antimicrobial replacer. Finally, the present invention relates to a method for reducing antimicrobial load of a cosmetic or pharmaceutical composition or homecare product comprising a natural polymer.

A seawater mineral extract derived from seawater having a salinity of from 3.4% Brix to 3.6% Brix, wherein the seawater mineral extract comprises a mineral salt content of at least 20% of the overall seawater extract.

Provided herein are alkaline water compositions and methods of using these compositions.

The present disclosure relates to, inter alia, a formulation in a package. The formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.

The disclosure relates to the method for alleviating skin irritation or inhibiting sebum production, which includes administering a composition including a compound represented by Chemical Formula 1, a salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof as an active ingredient to a subject in need of alleviating skin irritation or inhibiting sebum production, and specifically the composition can alleviate the irritation of the skin stimulated by ultraviolet rays, and more specifically, the composition can alleviate the skin irritation by reducing inflammatory factors in the cells of the skin stimulated by simultaneous stimulation of UVA and UVB ultraviolet rays, and in addition, specifically, it is possible to suppress the sebum production by inhibiting intracellular lipid synthesis with the composition, and more specifically, the sebum production of the skin can be suppressed by reducing the expression level of the factors related to intracellular lipid synthesis with the composition.

The present invention relates to a cosmetic or pharmaceutical, preferably dermatological, composition comprising or consisting of a liquid lipophilic component and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or for animal care. Additionally, the present invention relates to the use of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or of a mixture of two or more different specific alkanediols for improving the sensor), properties, i.e. skin sensation, of a cosmetic or pharmaceutical composition upon topical application, or as silicone replacer.

The present disclosure relates to, inter alia, a formulation comprising one or more active agents and one or more thermal stabilizing agents and is co-mingled with a first propellant that is a gas propellant prior to being filled under pressure into said package; the first propellant is added in sufficient amounts to be dispersed in the formulation; the package is under sufficient pressure suitable to expel the formulation as a whipped formulation upon application of external force on said formulation in said package. The present disclosure also relates to, inter alia, a method of preparing the disclosed formulation; a package comprising the disclosed formulation, and a method of using the disclosed formulation.

The present disclosure provides methods of preparing perivascular tissue lysates and methods of preparing mesenchymal stem cell (e.g., perivascular stem cell) lysates and total protein products from cultured cells (e.g., cultured perivascular stromal cells). The disclosure also features compositions containing such lysates and total protein products and methods of using the lysates in skincare applications, dermatological applications, cell culture applications, and to treat autoimmune or inflammatory diseases or conditions, local inflammation, and angiogenesis-related diseases or conditions.

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/′ receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.